Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

1 in Phase 3

Quick facts

Phase 3 pipeline

Irinotecan/Cetuximab · Oncology
Irinotecan inhibits topoisomerase I to damage cancer cell DNA, while cetuximab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy sensitivity.

Phase 2 pipeline

Bevacizumab and FOLFIRI · Oncology
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while FOLFIRI is a chemotherapy regimen that includes irinotecan, a topoisomerase I inhibitor.
Gemcitabina, Cisplatino

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

What is Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente's pipeline?

Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente has 1 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include Irinotecan/Cetuximab.

Sector hub: All tracked pharma companies